Portland, Oregon 97239


The primary goals of this study are to use optical coherence tomography (OCT) angiography (blood vessel mapping) to: 1. diagnose the presence of new blood vessels in wet age-related macular degeneration (AMD) 2. evaluate patients undergoing treatment for wet AMD 3. determine if reduced flow to the choroid is a risk factor for developing wet AMD.


Inclusion Criteria (Groups with wet AMD): - Adults aged 50 and older with clinical findings of treatment-naïve (never treated) neovascular AMD with active new blood vessel growth confirmed by clinical testing will be considered Inclusion Criteria (Group with healthy eyes) - No evidence of retinal disease - Refractive error greater than +3.00 diopters or -7.00 diopters (glasses Rx) - No recent eye surgery in the last 4 months - No significant cataract to interfere with the quality of the imaging Exclusion Criteria (All Groups): - Inability to give informed consent - Significant kidney disease - Blood pressure greater than 180/110 - Previous macular laser treatment - Inability to maintain stable fixation during OCT imaging - Visual acuity worse than 20/200



Primary Contact:

Principal Investigator
Steven Bailey, MD
Oregon Health and Science University

Omkar Thaware, B Optom, MSVS
Phone: 503-494-7398
Email: thaware@ohsu.edu

Backup Contact:

Email: romfhd@ohsu.edu
Denny Romfh, OD
Phone: 503-494-4351

Location Contact:

Portland, Oregon 97239
United States

Omkar Thaware, B Optom, MSVS
Phone: 503-494-7398
Email: thaware@ohsu.edu

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.